Lyell Immunopharma, Inc. (LYEL)
|Net Income (ttm)||-230.28M|
|Trading Day||June 22|
|Day's Range||16.00 - 16.88|
|52-Week Range||14.99 - 18.90|
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with ...
Lyell Immunopharma, Inc. has filed to go public with an IPO on the NASDAQ.
Lyell Immunopharma is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. We believe the key to effective cell therapy is the mastery of the identity, fate and function of cells to create living medicines. We take a systematic, interrogative, cell biology-driven approach to overcome what we view as the two major barriers to successful ACT – (1) T cell exhaustion and (2) lack of durable stemness – through the application of our proprietary genetic and epigenetic reprogramming technologies, G... [Read more...]
|IPO Date |
Jun 17, 2021
|Stock Exchange |
|Ticker Symbol |
In 2020, LYEL's revenue was $7.76 million, an increase of 1,080.52% compared to the previous year's $657,000. Losses were -$204.47 million, 58.0% more than in 2019.